<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02024477</url>
  </required_header>
  <id_info>
    <org_study_id>CV181-305</org_study_id>
    <nct_id>NCT02024477</nct_id>
  </id_info>
  <brief_title>Effect of Saxagliptin on EPCs as a Cellular Biomarker for Evaluating Endothelial Dysfunction in Early T2DM Patients</brief_title>
  <official_title>Effect of Saxagliptin (DPP-4 Inhibitor) on Endothelial Progenitor Cells (EPCs) as a Cellular Biomarker for Evaluating Endothelial Dysfunction in Early Type 2 Diabetes Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>George Washington University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>George Washington University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Type 2 diabetes is a national epidemic. Diabetes has undesirable effects on blood vessels
      which may contribute to heart disease. Endothelial Progenitor Cells(EPCs) are found in the
      blood . Research has shown that improving the survival of these special blood cells may
      decrease the harmful effects of diabetes on blood vessels and reduce or reverse heart
      disease. Saxagliptin is an FDA(Food and Drug Administration) approved prescription medicine
      used along with diet and exercise to lower blood sugar in people with Type 2 diabetes. It is
      in a class of diabetes medication called DPP-4 inhibitors. DPP-4 inhibitors have been shown
      to increase EPCs in patients with Type 2 diabetes.

      Hypothesis: We believe poor viability and function of EPCs in early diabetes ultimately
      affects the repair and regeneration of the endothelium and that prompt intervention using
      saxagliptin with another oral hypoglycemic agent, Metformin, may reduce or reverse
      cardiovascular risk by improving EPC survival and function above and beyond adequate glucose
      metabolism control.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Type 2 diabetes is a national epidemic 1,2 with significant macro and microvascular
      complications. Insulin resistance in prediabetes and early and late diabetes are associated
      with endothelial dysfunction.

      A few studies indicate that EPCs can act as a suitable bio-marker for monitoring
      cardiovascular morbidity. In this proposal we suggest that EPCs or CD34 positive cells can
      act as a suitable cellular biomarker for estimating and following endothelial dysfunction in
      early type 2 diabetes patients.

      EPCs have been used as a regenerative tool in ischemic myocardium and diabetic wound healing.
      Endothelial dysfunction with associated inflammation may be a consequence of excess
      super-oxide presence in a setting of diabetes which is a pro-oxidative stress condition
      causing EPC dysfunction and senescence. Therefore monitoring EPC number, function and gene
      expression may serve as a very useful cellular bio-marker for cardiovascular complications in
      early type 2 diabetes.

      Though lifestyle modification has been proposed as a main stay for prevention and treatment
      of early type 2 diabetes, several new therapies for diabetes have been developed in recent
      years. Incretins and incretin mimetics appear to hold promise. Oral DPP-4 inhibitors have
      been shown to increase EPCs in patients with type 2 diabetes reportedly via SDF-1 alpha
      up-regulation. Interestingly, up-regulation of SDF-1 alpha and vascular endothelial growth
      factor (VEGF), both chemotactic factors increase mobilization and recruitment of EPCs in the
      face of acute ischemic injury for repair and regeneration.

      Several studies have shown positive effect of incretins (Glucagon like peptide, GLP-1) and
      incretin receptor agonists (GLP-1 receptor agonists) on cardiovascular risk factors in type 2
      diabetes patients and even in patients with chronic heart failure and left ventricular
      dysfunction who do not have diabetes.

      DPP-4 Inhibitors may have cardio-protective effects of their own, as they increase
      bio-availability of endogenous GLP-1. They improve blood flow and nitric oxide production in
      endothelium. These are unique properties not demonstrated by other oral diabetes medications.
      The mechanism underlying these effects may be mediated by increased nitric oxide
      bioavailability but is not completely known. It is possible that Saxagliptin, a member of
      DPP-4 inhibitor group of drugs may be able to improve number and function of CD34+
      endothelial progenitor cells by up-regulating chemotactic agent SDF1 alpha (DPP-4 degrades
      SDF-1) and its receptor CXCR47, 20, 21, 30, 31.

      Poor viability and function of EPCs in early diabetes may ultimately affect the repair and
      regeneration of the endothelium and prompt intervention may reduce or reverse cardiovascular
      risk by improving EPC survival and function above and beyond adequate glucose metabolism
      control.

      Therefore we would like to explore the effect of saxagliptin in addition to lifestyle
      intervention, on number and function and gene expression of EPC and impact on endothelial
      dysfunction in type 2 diabetes.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">September 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CD34+ Endothelial Progenitor Cells Number</measure>
    <time_frame>Up to 12 weeks post saxagliptin</time_frame>
    <description>We will use patient's peripheral blood derived CD34+ cells looking at number of CD34+ Endothelial Progenitor Cell as % of the total Mononuclear cell population. Post saxagliptin will be compared to pre saxagliptin measurement</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CD 34+ Cell Function</measure>
    <time_frame>Up to 12 weeks post saxagliptin Up to 12 weeks post saxagliptin: Visit 1 at Baseline, Visit 2 at 6 weeks, and Visit 3 at 12 weeks</time_frame>
    <description>function of EPC cell as migration of CD34+ cells in response to SDF-1a ( 100 ng/mL). Results are expressed in fluorescence ratio between cells exposed to the chemotactic factor and cells exposed to chemo attractant-free media ( control) followed by lysis in presence of CyQuant GR dye.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Endothelial Inflammatory Marker hsCRP</measure>
    <time_frame>Baseline 6 and 12 weeks post saxagliptin</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Lipid Profile LDL/HDL</measure>
    <time_frame>Baseline, 6 and 12 weeks post saxagliptin</time_frame>
    <description>ratio of LDL over HDL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycemic Control</measure>
    <time_frame>Baseline, 6 and 12 weeks post saxagliptin</time_frame>
    <description>measuring HbA1c levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adiposity</measure>
    <time_frame>Baseline, 6 and 12 weeks post saxagliptin</time_frame>
    <description>measured using a Tanita Body Composition Fat Analyzer scale, measured as percentage body fat</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arterial Stiffness</measure>
    <time_frame>Baseline, 6 and 12 weeks post saxagliptin</time_frame>
    <description>Arterial stiffness assessed using Vascular Flow and wave measurement equipment, SphygmoCor CP system from ATCOR. Reported as Augmentation Index adjusted for a heart rate of 75. Augmentation index (AIx) is a measure of systemic arterial stiffness derived from the ascending aortic pressure waveform. Lower the value, better correlated outcome as positive augmentation represents stiffer artery.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo 1 pill daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>saxagliptin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Saxagliptin 5mg once daily for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saxagliptin</intervention_name>
    <description>5 mg tablet once daily for 12 weeks</description>
    <arm_group_label>saxagliptin</arm_group_label>
    <other_name>Onglyza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 tablet daily for 12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Adults aged 40-70 years.

          2. Diagnosis of type 2 diabetes within the previous 8 years using criteria of the
             American Diabetes Association

          3. Currently treated with no hypoglycemic agents other than a stable dose (&gt;3 months) of
             metformin (≥1.0 to ≤2 grams daily).

          4. HbA1C between 6 to 9% (both inclusive)

          5. BMI 25 to 39.9 kg/m2 (both inclusive)

        Exclusion Criteria:

          1. Contraindications for moderate exercise

          2. Implanted devices (e.g., pacemakers) that may interact with Tanita scale

          3. Previous coronary or cerebrovascular event within 6 months of screening or active or
             clinically significant coronary and/or peripheral vascular disease.

          4. Low hematocrit &lt;28 Units

          5. Pre-existing liver disease and/or ALT and AST &gt;2.5X's UNL

          6. Kidney disease (serum creatinine levels ≥1.5 mg/dL for men, ≥1.4 mg/dL for
             women,Creatinine Clearance ≤50 mL/min)

          7. History of pancreatitis, or cancer (except basal cell carcinoma)

          8. Statin use started (or dose change) in the last 3 months.

          9. Use of oral or injectable anti-diabetic medication other than Metformin

         10. Use of any form of consistent-long term steroid medication (oral, inhaled injected or
             nasal) within the last 3 months

         11. Systolic BP&gt; 140 mmHg and diastolic BP&gt; 90 mmHg

         12. Active wounds or recent surgery within 3 months.

         13. Inflammatory disease, or current use of anti-inflammatory drugs

         14. triglycerides &gt;400 mg/dL

         15. untreated hyper/hypothyroidism Additionally, patients who are active smokers, patients
             who are pregnant, nursing women, and post menopausal women who are on hormone
             replacement therapy will be excluded.

        Patients on low dose oral contraceptives will be allowed to participate as these
        formulations contain lesser amount of estrogens.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sabyaschi Sen, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>George Washington University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical Faculty Associates Inc</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>December 13, 2013</study_first_submitted>
  <study_first_submitted_qc>December 30, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2013</study_first_posted>
  <results_first_submitted>August 14, 2018</results_first_submitted>
  <results_first_submitted_qc>January 10, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">January 29, 2019</results_first_posted>
  <last_update_submitted>January 30, 2019</last_update_submitted>
  <last_update_submitted_qc>January 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>George Washington University</investigator_affiliation>
    <investigator_full_name>Sabyasachi Sen</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>endothelial cells</keyword>
  <keyword>cellular biomarker</keyword>
  <keyword>endothelial dysfunction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Saxagliptin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is no current plan for sharing IPD with other researchers.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 21, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/77/NCT02024477/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from clinic of the Principle Investigator and Sub-Investigators involved in the trial. First patient was recruited on 26 Nov 2013, last patient was recruited on 24 May 2016.</recruitment_details>
      <pre_assignment_details>Screening period lasted 2 weeks. No wash-out or run-in periods were necessary.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo: 1 tablet daily for 12 weeks</description>
        </group>
        <group group_id="P2">
          <title>Saxagliptin</title>
          <description>Saxagliptin: 5 mg tablet once daily for 12 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo: 1 tablet daily for 12 weeks</description>
        </group>
        <group group_id="B2">
          <title>Saxagliptin</title>
          <description>Saxagliptin: 5 mg tablet once daily for 12 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
            <count group_id="B2" value="21"/>
            <count group_id="B3" value="42"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.4" spread="8.5"/>
                    <measurement group_id="B2" value="58.3" spread="5.7"/>
                    <measurement group_id="B3" value="57.3" spread="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>Kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="202.3" spread="38.7"/>
                    <measurement group_id="B2" value="202.7" spread="24.5"/>
                    <measurement group_id="B3" value="202.5" spread="31.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.5" spread="4.8"/>
                    <measurement group_id="B2" value="32.3" spread="4.2"/>
                    <measurement group_id="B3" value="31.9" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of Diabetes Mellitus II</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.5" spread="1.8"/>
                    <measurement group_id="B2" value="3.7" spread="2.4"/>
                    <measurement group_id="B3" value="3.6" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HBA1c</title>
          <units>mmol/mol</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.6" spread="0.5"/>
                    <measurement group_id="B2" value="7.0" spread="0.8"/>
                    <measurement group_id="B3" value="6.8" spread="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting Glucose</title>
          <units>mg/Dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="114.8" spread="25"/>
                    <measurement group_id="B2" value="127.4" spread="35.9"/>
                    <measurement group_id="B3" value="121.1" spread="30.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>eGFR</title>
          <units>mL/min/1.73</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="93.7" spread="16.7"/>
                    <measurement group_id="B2" value="98.9" spread="14.5"/>
                    <measurement group_id="B3" value="96.3" spread="15.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>CD34+ Endothelial Progenitor Cells Number</title>
        <description>We will use patient's peripheral blood derived CD34+ cells looking at number of CD34+ Endothelial Progenitor Cell as % of the total Mononuclear cell population. Post saxagliptin will be compared to pre saxagliptin measurement</description>
        <time_frame>Up to 12 weeks post saxagliptin</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: 1 tablet daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Saxagliptin</title>
            <description>Saxagliptin: 5 mg tablet once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>CD34+ Endothelial Progenitor Cells Number</title>
          <description>We will use patient's peripheral blood derived CD34+ cells looking at number of CD34+ Endothelial Progenitor Cell as % of the total Mononuclear cell population. Post saxagliptin will be compared to pre saxagliptin measurement</description>
          <units>% of Mononuclear Cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="0.3"/>
                    <measurement group_id="O2" value="2.8" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>CD 34+ Cell Function</title>
        <description>function of EPC cell as migration of CD34+ cells in response to SDF-1a ( 100 ng/mL). Results are expressed in fluorescence ratio between cells exposed to the chemotactic factor and cells exposed to chemo attractant-free media ( control) followed by lysis in presence of CyQuant GR dye.</description>
        <time_frame>Up to 12 weeks post saxagliptin Up to 12 weeks post saxagliptin: Visit 1 at Baseline, Visit 2 at 6 weeks, and Visit 3 at 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: 1 tablet daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Saxagliptin</title>
            <description>Saxagliptin: 5 mg tablet once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>CD 34+ Cell Function</title>
          <description>function of EPC cell as migration of CD34+ cells in response to SDF-1a ( 100 ng/mL). Results are expressed in fluorescence ratio between cells exposed to the chemotactic factor and cells exposed to chemo attractant-free media ( control) followed by lysis in presence of CyQuant GR dye.</description>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 1 - Week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="0.1"/>
                    <measurement group_id="O2" value="1.05" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2 - Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.05" spread="0.15"/>
                    <measurement group_id="O2" value="1.55" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3 - Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="0.06"/>
                    <measurement group_id="O2" value="1.2" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Endothelial Inflammatory Marker hsCRP</title>
        <time_frame>Baseline 6 and 12 weeks post saxagliptin</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: 1 tablet daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Saxagliptin</title>
            <description>Saxagliptin: 5 mg tablet once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Endothelial Inflammatory Marker hsCRP</title>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 1 - Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="0.6"/>
                    <measurement group_id="O2" value="2.8" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2 - Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" spread="0.8"/>
                    <measurement group_id="O2" value="2.7" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3 - Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" spread="0.7"/>
                    <measurement group_id="O2" value="2.4" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fasting Lipid Profile LDL/HDL</title>
        <description>ratio of LDL over HDL</description>
        <time_frame>Baseline, 6 and 12 weeks post saxagliptin</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: 1 tablet daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Saxagliptin</title>
            <description>Saxagliptin: 5 mg tablet once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting Lipid Profile LDL/HDL</title>
          <description>ratio of LDL over HDL</description>
          <units>ratio of LDL over HDL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 1 - Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="0.2"/>
                    <measurement group_id="O2" value="1.8" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2 - Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="0.2"/>
                    <measurement group_id="O2" value="1.8" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3 - Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="0.2"/>
                    <measurement group_id="O2" value="1.8" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glycemic Control</title>
        <description>measuring HbA1c levels</description>
        <time_frame>Baseline, 6 and 12 weeks post saxagliptin</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: 1 tablet daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Saxagliptin</title>
            <description>Saxagliptin: 5 mg tablet once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Glycemic Control</title>
          <description>measuring HbA1c levels</description>
          <units>% of Glycosylated Hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 1 - Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6" spread="0.1"/>
                    <measurement group_id="O2" value="7.0" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2 - Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6" spread="0.1"/>
                    <measurement group_id="O2" value="6.8" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3 - Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5" spread="0.1"/>
                    <measurement group_id="O2" value="6.7" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adiposity</title>
        <description>measured using a Tanita Body Composition Fat Analyzer scale, measured as percentage body fat</description>
        <time_frame>Baseline, 6 and 12 weeks post saxagliptin</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: 1 tablet daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Saxagliptin</title>
            <description>Saxagliptin: 5 mg tablet once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Adiposity</title>
          <description>measured using a Tanita Body Composition Fat Analyzer scale, measured as percentage body fat</description>
          <units>% of Body fat</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 1 - Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34" spread="2"/>
                    <measurement group_id="O2" value="37" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2 - Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34" spread="2"/>
                    <measurement group_id="O2" value="36.5" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3 - Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35" spread="2"/>
                    <measurement group_id="O2" value="36" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Arterial Stiffness</title>
        <description>Arterial stiffness assessed using Vascular Flow and wave measurement equipment, SphygmoCor CP system from ATCOR. Reported as Augmentation Index adjusted for a heart rate of 75. Augmentation index (AIx) is a measure of systemic arterial stiffness derived from the ascending aortic pressure waveform. Lower the value, better correlated outcome as positive augmentation represents stiffer artery.</description>
        <time_frame>Baseline, 6 and 12 weeks post saxagliptin</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: 1 tablet daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Saxagliptin</title>
            <description>Saxagliptin: 5 mg tablet once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Arterial Stiffness</title>
          <description>Arterial stiffness assessed using Vascular Flow and wave measurement equipment, SphygmoCor CP system from ATCOR. Reported as Augmentation Index adjusted for a heart rate of 75. Augmentation index (AIx) is a measure of systemic arterial stiffness derived from the ascending aortic pressure waveform. Lower the value, better correlated outcome as positive augmentation represents stiffer artery.</description>
          <units>Augmentation Index</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 1: Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.4" spread="2.4"/>
                    <measurement group_id="O2" value="24.1" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2: Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26" spread="3.9"/>
                    <measurement group_id="O2" value="22.5" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3: Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.3" spread="2.3"/>
                    <measurement group_id="O2" value="23.1" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>20 weeks</time_frame>
      <desc>from the day ICF was signed till 1 month after V3.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo: 1 tablet daily for 12 weeks</description>
        </group>
        <group group_id="E2">
          <title>Saxagliptin</title>
          <description>Saxagliptin 5mg once daily for 12 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertensive Urgency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Limitations of our study may include the relatively short duration of 12 week Saxagliptin therapy, which may have been inadequate to see significant changes in certain clinical and cellular parameters.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr Saby Sen</name_or_title>
      <organization>The George Washington University</organization>
      <phone>202-994-8560</phone>
      <email>ssen1@gwu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

